Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

822 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality.
Pieber TR, Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pratley RE, Woo V, Heller S, Lange M, Brown-Frandsen K, Moses A, Barner Lekdorf J, Lehmann L, Kvist K, Buse JB; DEVOTE Study Group. Pieber TR, et al. Among authors: lehmann l. Diabetologia. 2018 Jan;61(1):58-65. doi: 10.1007/s00125-017-4422-0. Epub 2017 Sep 15. Diabetologia. 2018. PMID: 28913543 Free PMC article. Clinical Trial.
Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial.
Rodbard HW, Bode BW, Harris SB, Rose L, Lehmann L, Jarlov H, Thurman J; Dual Action of Liraglutide and insulin degludec (DUAL) IV trial investigators. Rodbard HW, et al. Among authors: lehmann l. Diabet Med. 2017 Feb;34(2):189-196. doi: 10.1111/dme.13256. Epub 2016 Oct 7. Diabet Med. 2017. PMID: 27589252 Free PMC article. Clinical Trial.
Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin.
Vilsbøll T, Blevins TC, Jodar E, Poulter N, Tentolouris N, Ross Agner BF, Lehmann L, Leiter LA. Vilsbøll T, et al. Among authors: lehmann l. Diabetes Obes Metab. 2019 Jun;21(6):1506-1512. doi: 10.1111/dom.13675. Epub 2019 Apr 8. Diabetes Obes Metab. 2019. PMID: 30785655 Free PMC article.
The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial.
Linjawi S, Bode BW, Chaykin LB, Courrèges JP, Handelsman Y, Lehmann LM, Mishra A, Simpson RW. Linjawi S, et al. Diabetes Ther. 2017 Feb;8(1):101-114. doi: 10.1007/s13300-016-0218-3. Epub 2016 Dec 10. Diabetes Ther. 2017. PMID: 27943107 Free PMC article.
Use of the FallAkte Plus System as an IT Infrastructure for the North Rhine-Westphalian General Practice Research Network: Mixed Methods Usability Study.
Bozorgmehr A, Thiem SK, Wild D, Reinsdorff M, Vollmar HC, Kappernagel A, Schloessler K, Weissbach S, Pentzek M, Dehnen D, Drexler J, Mueller BS, Pilic L, Lehmann L, Loescher S, Hohmann ED, Frank F, Ates G, Kersten S, Mortsiefer A, Aretz B, Weltermann B. Bozorgmehr A, et al. Among authors: lehmann l. JMIR Form Res. 2024 May 20;8:e53206. doi: 10.2196/53206. JMIR Form Res. 2024. PMID: 38767942 Free article.
Dysfunction of the adhesion G protein-coupled receptor latrophilin 1 (ADGRL1/LPHN1) increases the risk of obesity.
Dietzsch AN, Al-Hasani H, Altschmied J, Bottermann K, Brendler J, Haendeler J, Horn S, Kaczmarek I, Körner A, Krause K, Landgraf K, Le Duc D, Lehmann L, Lehr S, Pick S, Ricken A, Schnorr R, Schulz A, Strnadová M, Velluva A, Zabri H, Schöneberg T, Thor D, Prömel S. Dietzsch AN, et al. Among authors: lehmann l. Signal Transduct Target Ther. 2024 Apr 26;9(1):103. doi: 10.1038/s41392-024-01810-7. Signal Transduct Target Ther. 2024. PMID: 38664368 Free PMC article.
822 results